Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

NovoBoard: a comprehensive framework for evaluating the false discovery rate and accuracy of de novo peptide sequencing

ABSTRACT: De novo peptide sequencing is a fundamental research area in mass spectrometry (MS) based proteomics. However, those methods have often been evaluated using a couple of simple metrics that do not fully reflect their overall performance. Moreover, there has not been an established method to estimate the false discovery rate (FDR) and the significance of de novo peptide-spectrum matches (PSMs). Here we propose NovoBoard, a comprehensive framework to evaluate the performance of de novo peptide sequencing methods. The framework consists of diverse benchmark datasets (including tryptic, nontryptic, immunopeptidomics, and different species), and a standard set of accuracy metrics to evaluate the fragment ions, amino acids, and peptides of the de novo results. More importantly, a new approach is designed to evaluate de novo peptide sequencing methods on target-decoy spectra and to estimate their FDRs. Our results thoroughly reveal the strengths and weaknesses of different de novo peptide sequencing methods, and how their performances depend on specific applications and the types of data. Our FDR estimation also shows that some tools may perform better than the others in distinguishing between de novo PSMs and random matches, and can be used to assess the significance of de novo PSMs.

INSTRUMENT(S): Q Exactive

ORGANISM(S): Homo Sapiens (human)

SUBMITTER: Ngoc Hieu Tran

LAB HEAD: Baozhen Shan

PROVIDER: PXD055277 | Pride | 2024-08-28

REPOSITORIES: Pride

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	2017-12-4_ABRF_200_DDA1.mgf	Mgf
	eval_ABRF.zip	Other
	eval_athaliana.zip	Other
	eval_ecoli.zip	Other
	eval_hla.zip	Other

Items per page:

1 - 5 of 10

Similar Datasets

Application of de novo sequencing to large-scale complex proteomics datasets

Project description:Dependent on concise, pre-defined protein sequence databases, traditional search algorithms perform poorly when analyzing mass spectra derived from wholly uncharacterized protein products. Conversely, de novo peptide sequencing algorithms can interpret mass spectra without relying on reference databases. However, such algorithms have been difficult to apply to complex protein mixtures, in part due to a lack of methods for automatically validating de novo sequencing results. Here, we present novel metrics for benchmarking de novo sequencing algorithm performance on large scale proteomics datasets, and present a method for accurately calibrating false discovery rates on de novo results. We also present a novel algorithm (LADS) which leverages experimentally disambiguated fragmentation spectra to boost sequencing accuracy and sensitivity. LADS improves sequencing accuracy on longer peptides relative to other algorithms and improves discriminability of correct and incorrect sequences. Using these advancements, we demonstrate accurate de novo identification of peptide sequences not identifiable using database search-based approaches.

2016-01-12 | PXD003317 | Pride

pXg: Comprehensive identification of noncanonical MHC-I-associated peptides from de novo peptide sequencing using RNA-Seq reads

Project description:Discovering noncanonical peptides has been a common application of proteogenomics. Recent studies suggest that certain noncanonical peptides, known as ncMAPs (noncanonical MHC-I-associated peptides), that bind to major histocompatibility complex I may make good immunotherapeutic targets. De novo peptide sequencing is a great way to find ncMAPs since it can detect peptide sequences from their tandem mass spectra without using any sequence databases. However, this strategy hasn’t been widely applied for ncMAP identification because there is not a good way to estimate its false-positive rates. In order to completely and accurately identify immunopeptides using de novo peptide sequencing, we describe a unique pipeline called pXg. In contrast to current pipelines, it makes use of genomic data, RNA-Seq abundance and sequencing quality, in addition to proteomic features to increase the sensitivity and specificity of peptide identification. We show that the peptide-spectrum match quality and genetic traits have a clear relationship, showing that they can be utilized to evaluate peptide-spectrum matches. From ten samples, we found 24,449 cMAPs (canonical MHC-I-associated peptides) and 956 ncMAPs by using a target-decoy competition. 387 ncMAPs and 1,611 cMAPs were novel identifications that had not yet been published. We discovered 11 ncMAPs produced from a squirrel monkey retrovirus in human cell lines in addition to the 2 ncMAPs originating from a complementarity determining region 3 in an antibody thanks to the unrestricted search space assumed by de novo sequencing. These entirely new identifications show that pXg can make the most of de novo peptide sequencing's advantages and its potential use in the search for new immunotherapeutic targets.

2024-02-28 | PXD048006 | Pride

Combining de novo peptide sequencing algorithms, a synergistic approach to boost both identifications and confidence in bottom-up proteomics

Project description:Complex MS-based proteomics datasets are usually analyzed by protein database-searches. While this approach performs considerably well for sequenced organisms, direct inference of peptide sequences from tandem mass spectra, i.e. de novo peptide sequencing, oftentimes is the only way to obtain information when protein databases are absent. However, available algorithms suffer from drawbacks such as lack of validation and often high rates of false positive hits (FP). Here we present a simple method of combining results from commonly available de novo peptide sequencing algorithms, which in conjunction with minor tweaks in data acquisition ensues lower empirical FDR compared to the analysis using single algorithms. Results were validated using state-of-the art database search algorithms as well specifically synthesized reference peptides. Thus, we could increase the number of PSMs meeting a stringent FDR of 5% more than threefold compared to the single best de novo sequencing algorithm alone, accounting for an average of 11,120 PSMs (combined) instead of 3,476 PSMs (alone) in triplicate 2 h LC-MS runs of tryptic HeLa digestion.

2019-09-25 | PXD005280 | Pride

P-VIS: internally-controlled validation of mass spectrometry-based peptide identifications

Project description:Peptide-Spectrum Match (PSM) Validation with Internal Standards (P-VIS) is an objective approach to validating individual PSMs. A biological sample is analyzed by LC-MS/MS and the data are searched using a traditional approach such as a database search or de novo sequencing. A PSM of interest is identified, and a synthetic version of the putative peptide is obtained. Internal standard peptides (ISPs) are spiked into both the biological sample and the validation peptide sample and both samples are analyzed by LC-MS/MS. Using PSM_validator (https://github.com/Delong-Lab/PSM_validator/releases), an open-source program we created to implement the P-VIS workflow, both the fragmentation spectrum and the chromatographic retention time for the peptide of interest in the biological sample are compared to those of the validation peptide. The same comparisons are made for each of the ISPs, and these results are used to establish a prediction interval for valid matches. If the values for the comparisons between the biological and validation peptide fall within the prediction intervals, the match is considered valid. This submission contains the data and P-VIS results from a study aimed at benchmarking the P-VIS workflow.

2020-09-21 | PXD020901 | Pride

E. coli mirror LC-MS/MS - Precision de novo peptide sequencing using mirror proteases of Ac-LysargiNase and trypsin for large-scale proteomics

Project description:Precision de novo peptide sequencing using mirror proteases of Ac-LysargiNase and trypsin for large-scale proteomicsPrecision de novo peptide sequencing using mirror proteases of Ac-LysargiNase and trypsin for large-scale proteomics

2019-01-11 | PXD008688 | Pride

full length protein sequencing method based on less specific and unspecific hydrolysis strategies 2

Project description:We describe a new strategy for LC-MS/MS based full length protein sequencing. Protein samples were unspecific hydrolyzed by three different methods(proteinase K, papain and microwave-assisted acid hydrolysis) to improve overlapping degree of peptides. After LC-MS/MS analysis, peptide sequences were gernated by de novo peptide sequencing program Pnovo. A new sequence assembly program, based on de brujin graph and Overlap-Layout-Consensus strategy, was desined to generate full length protein sequence using Pnovo results.

2022-02-15 | PXD030203 | Pride

De novo nine-species benchmark peptide identifications for Casanovo and other methods

Project description:Predicted peptides for the 9-species de novo sequencing benchmark MSV000090982 as described in Yilmaz et al. [Yilmaz2023]. FTP directory contains outputs of 5 de novo peptide sequencing methods on the 9-species benchmark: Casanovo, Casanovo_bm (benchmark), PointNovo, DeepNovo and Novor. [Yilmaz2023] M. Yilmaz*, W. Fondrie*, W. Bittremieux*, R. Nelson, V. Ananth, S. Oh, and W. Noble,"Sequence-to-sequence translation from mass spectra to peptides with a transformer model", bioRxiv, 2023

2024-02-01 | MSV000093979 | MassIVE

Zhang2020 - Draft metabolic reconstruction model of Atlantic cod liver generated from gadMorTrinity and iHepatocyte2322

Project description:This is an auto-generated model with COBRA Matlab toolbox. The gadMorTrinigy de novo Trinity transcript assembly and peptide sequences are available at https://doi.org/10.6084/m9.figshare.c.5168303.v2

2020-10-26 | MODEL2010090002 | BioModels

Estimating the Contribution of Proteasomal Spliced Peptides to the HLA-I Ligandome

Project description:Spliced peptides are short protein fragments spliced together in the proteasome by peptide bond formation. True estimation of the contribution of proteasome-spliced peptides (PSPs) to the global Human Leukocyte Antigen (HLA) ligandome is critical. A recent study suggested that PSPs contribute up to 30% of the HLA ligandome. We performed a thorough reanalysis of the reported results using multiple computational tools and various validation steps and concluded that only a fraction of the proposed PSPs passes the quality filters. To better estimate the actual number of PSPs, we present an alternative workflow. We performed de-novo sequencing of the HLA-peptide spectra and discarded all de-novo sequences found in the UniProt database. We checked whether the remaining de-novo sequences could match spliced peptides from human proteins. The spliced sequences were appended to the UniProt fasta file, which was searched by two search tools at a FDR of 1%. We find that 2-6% of the HLA ligandome could be explained as spliced protein fragments. The majority of these potential PSPs have good peptide-spectrum match properties and are predicted to bind the respective HLA molecules. However, it remains to be shown how many of these potential PSPs actually originate from proteasomal splicing events.

2018-09-03 | PXD010793 | Pride

Prochlorococcus marinus MED4 shotgun proteome dataset from “Protein cycling in the eastern tropical North Pacific oxygen deficient zone: a de novo-discovery peptidomic approach”

Project description:For this manuscript, the Prochlorococcus MED4 strain shotgun proteome dataset was used for benchmarking a de novo-directed sequencing approach. De novo peptide sequencing, where the sequence of amino acids is determined directly from mass spectra rather than by comparison (or peptide spectrum matching) to a selected database. We perform a benchmarking experiment using Prochlorococcus culture data, demonstrating de novo peptides are sufficiently accurate and taxonomically specific to be useful in environmental studies. The MED4 dataset herein represents the output from peptide spectrum matching using COMET within the transproteomic pipeline (TPP). Additional MED4 data outside this manuscript are included for both trypsin and Glu-C protease digestions as well as TPP output for post-translational modification searches. De novo output data derived from Peaks Studio can be found by referencing the manuscript publication.

2022-01-06 | PXD027589 | Pride